Custom Protein Generation

Drug Substance Manufacture

Drug Product Fill & Finish




Antibody Drug Conjugates

Technologies & Platforms


Launching A New Era in Antibody Drug Development

6-18 months faster development and no CMC challenges

WuXiBody™ is an innovative, proprietary technology platform developed by WuXi Biologics for the expanding field of bispecific antibodies. Based on novel engineering, the platform can expedite the drug development process by 6-18 months and significantly reduce cost-of-goods.  The WuXiBody™ platform enables almost any mAb sequence pair to be assembled into the bispecific construct and its unique structural flexibility makes the platform convenient to build various formats with different valency (e.g., 2, 3 or 4 binding sites).

WuXiBody™ Development/CMC Advantages

  • Saves 6-18 months of development time
  • Reduces manufacturing costs by as much as 90%
  • High protein expression in CHO cells (5 – 16 g/L)
  • No aggregation issues
  • Can be used in both fed-batch and concentrated fed-batch production
  • Easy, single-step purification of >95% using Protein A
  • Very stable: >2 weeks in serum at 37 °C
  • No solubility issues: > 30 mg/ml

WuXiBody™ Bispecific Engineering Advantages

  • Almost any mAb sequence can be used to build bispecifics in our platform
  • Available in both symmetric and asymmetric formats
  • Accommodates different valency formats (bi, tri and tetra) based on project needs and biology
  • Designed so that bispecific Ab can be purified using the same scheme as monoclonal antibodies
  • Typical in vivo half-life as mAbs
  • Engineered to achieve low immunogenicity in vivo by using natural sequences